Luis Álvarez-Vallina, Scientific Director at Banc de Sang I Teixits, shared on LinkedIn:
“Pleased to share our new paper in Journal of Controlled Release, in collaboration with Kenneth A. Howard and his team at Aarhus University: ‘A modular nucleic acid-albumin biomolecular platform for multifunctional drug designs.’
This work combines albumin genetic fusion with programmable oligonucleotide assembly to integrate an EGFR×CD3 T cell engager and a PD-L1-blocking single-domain antibody into a modular biomolecular platform: Albu-CiTE. The platform preserves target binding and FcRn engagement while enabling checkpoint inhibition and T cell-mediated tumor killing. Its modular architecture offers opportunities to explore therapeutic combinations and tune half-life through albumin engineering.
A pleasure to contribute to this multidisciplinary collaboration. Congratulations to all co-authors.”
Title: A modular nucleic acid-albumin biomolecular platform for multifunctional drug designs
Authors: Elisabeth Fuchs, Anders Dinesen, Sui Ching Ong, Yonghui Zhang, Aina Karen Anthi, Imke Rudnik-Jansen, Ole A. Mandrup, Marwa Elkhashab, Archie Wall, Esben S. Sørensen, Jesper Wengel, James R. Baker, Jan Terje Andersen, Luis Alvarez-Vallina, Kenneth A. Howard
Read the Full Article.
You can also read: Luis Álvarez-Vallina։ Pharmacological Control Advances STAb-T Cancer Immunotherapy